Equities research analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $317.90 million in sales for the current quarter, Zacks reports. Eleven analysts have issued estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $290.00 million and the highest estimate coming in at $347.10 million. Neurocrine Biosciences reported sales of $247.90 million in the same quarter last year, which indicates a positive year-over-year growth rate of 28.2%. The company is scheduled to report its next quarterly earnings results on Thursday, February 3rd.
On average, analysts expect that Neurocrine Biosciences will report full-year sales of $1.14 billion for the current fiscal year, with estimates ranging from $1.09 billion to $1.17 billion. For the next fiscal year, analysts expect that the company will post sales of $1.41 billion, with estimates ranging from $1.31 billion to $1.52 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, November 1st. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.28). Neurocrine Biosciences had a return on equity of 35.89% and a net margin of 41.59%. The company had revenue of $296.00 million during the quarter, compared to analysts’ expectations of $297.02 million. During the same period in the prior year, the firm earned ($0.62) EPS. Neurocrine Biosciences’s revenue for the quarter was up 14.5% compared to the same quarter last year.
A number of equities analysts have weighed in on NBIX shares. SVB Leerink reissued a “market perform” rating on shares of Neurocrine Biosciences in a research report on Monday, October 18th. Zacks Investment Research lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday. Citigroup…
